Prolonging survival in prostate cancer: chemotherapy will have an important role.
Parker
Chris
C
Academic Unit of Radiotherapy & Oncology, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK. Chris.Parker@icr.ac.uk
Emberton
Mark
M
D000726:Androgen Antagonists / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage
D000726:Androgen Antagonists; D043823:Taxoids; D000077143:Docetaxel; D011239:Prednisolone; D008942:Mitoxantrone